Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

A Role for FACT in Repopulation of Nucleosomes at Inducible Genes

  • Warren P. Voth,

    Affiliation Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, United States of America

  • Shinya Takahata,

    Address Current address: Bioorganic Chemistry Lab, Department of Chemistry, Faculty of Science, Hokkaido University, Sapporo City, Hokkaido, Japan

    Affiliation Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, United States of America

  • Joy L. Nishikawa,

    Affiliations Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, United States of America, Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America

  • Benjamin M. Metcalfe,

    Affiliation Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, United States of America

  • Anders M. Näär,

    Affiliations Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, United States of America, Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America

  • David J. Stillman

    david.stillman@path.utah.edu

    Affiliation Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, United States of America

A Role for FACT in Repopulation of Nucleosomes at Inducible Genes

  • Warren P. Voth, 
  • Shinya Takahata, 
  • Joy L. Nishikawa, 
  • Benjamin M. Metcalfe, 
  • Anders M. Näär, 
  • David J. Stillman
PLOS
x

Abstract

Xenobiotic drugs induce Pleiotropic Drug Resistance (PDR) genes via the orthologous Pdr1/Pdr3 transcription activators. We previously identified the Mediator transcription co-activator complex as a key target of Pdr1 orthologs and demonstrated that Pdr1 interacts directly with the Gal11/Med15 subunit of the Mediator complex. Based on an interaction between Pdr1 and the FACT complex, we show that strains with spt16 or pob3 mutations are sensitive to xenobiotic drugs and display diminished PDR gene induction. Although FACT acts during the activation of some genes by assisting in the nucleosomes eviction at promoters, PDR promoters already contain nucleosome-depleted regions (NDRs) before induction. To determine the function of FACT at PDR genes, we examined the kinetics of RNA accumulation and changes in nucleosome occupancy following exposure to a xenobiotic drug in wild type and FACT mutant yeast strains. In the presence of normal FACT, PDR genes are transcribed within 5 minutes of xenobiotic stimulation and transcription returns to basal levels by 30–40 min. Nucleosomes are constitutively depleted in the promoter regions, are lost from the open reading frames during transcription, and the ORFs are wholly repopulated with nucleosomes as transcription ceases. While FACT mutations cause minor delays in activation of PDR genes, much more pronounced and significant defects in nucleosome repopulation in the ORFs are observed in FACT mutants upon transcription termination. FACT therefore has a major role in nucleosome redeposition following cessation of transcription at the PDR genes, the opposite of its better-known function in nucleosome disassembly.

Introduction

Fungal disease remains a serious clinical concern, notably in an increasingly immunocompromised population, and especially given newly emerging fungal pathogens [1][3]. Drug treatment using an array of antifungal compounds often becomes ineffectual due to the ability of pathogens to overproduce membrane-associated broad-specificity xenobiotic efflux pumps, rendering them resistant to therapy [4]. These transport proteins are members of the ubiquitous and diverse ATP Binding Cassette (ABC) superfamily, which have a broad spectrum of roles in many phyla, including MDR (Multi-Drug Resistance) in cancer chemotherapy, antibiotic, herbicide, and other cytotoxic compound resistance, as well as in cellular homeostatic processes [5][9]. ABC members in Saccharomyces cerevisiae are similarly diverse, but the subset that confers resistance to antifungal toxins are encoded by the PDR (Pleiotropic Drug Resistance) genes [10][14].

Xenobiotic-induced expression of PDR efflux pump genes is complex, but is primarily programmed by the zinc-cluster transcription factor Pdr1 [15][17], along with the orthologous Pdr3 factor [18], [19], which are constitutively bound to PDRE sequences in PDR promoters, even in the absence of toxin [20]. Gene regulatory cofactors including the histone modifier SAGA and chromatin remodeler Swi/Snf have been shown to be recruited to PDR target gene promoters, and implicated in their activation [20]. Screens for mutations causing greater PDR1-dependent drug sensitivity have also indicated the HDAC Rpd3L may have a role in PDR gene activation [21]. Our previous work demonstrated that Pdr1 is capable of binding directly to antifungals and other xenobiotics, presumably causing a conformational change liberating the carboxyl-terminal transactivation domain, which can then productively engage transcription coactivators [22], [23]. We also showed that xenobiotic-activated Pdr1 promotes recruitment of the Mediator coactivator to the PDR5 promoter through direct interaction of the KIX domain in its Gal11 component, and that Gal11 and other modules of Mediator are necessary for the PDR response in both Saccharomyces as well as pathogenic Candida yeasts [22], [23].

FACT (FAcilitates Chromatin Transcription [24]) is an abundant, essential, highly conserved chromatin altering factor in eukaryotes composed of a heterodimer of Spt16 [25] and the HMG domain containing SSRP1 [26], [27] in non-fungal eukaryotes. In fungi, Spt16 complexes with the SSRP1 truncated homolog Pob3 but the HMG domain lies in a separate protein, Nhp6 [28], that associates with the FACT core supra-stoichiometrically [29][31]. Both Spt16 and Pob3 each carry a double pleckstrin homology (PH) domain as well as other protein binding domains [32], [33]. FACT is able to reorganize the interaction of DNA with histones in a nucleosomal context in vitro, but in a way mechanistically different than ATP-dependent remodelers [34]. Lack of FACT function in vivo results in a number of both replication and transcription phenotypes [31], [35][37]. A role for FACT in transcriptional elongation is supported by its ability to stimulate transcription through a chromatin barrier in vitro [24], its association with elongation factors [38], [39], and the presence of FACT at transcribed regions of genes in vivo [40], [41]. FACT is modeled as both disassembling and reassembling nucleosomes during elongation [42], with the importance of the reassembly role demonstrated by the observation that FACT mutants activate cryptic TATA elements because of inadequate restoration of repressive chromatin following transcription [40], [43]. There is also evidence that FACT regulates transcription initiation by affecting the accessibility of promoter regions to initiation factors and by participating in nucleosome eviction [37], [44][47]. FACT has therefore been implicated in both removal and assembly of nucleosomes prior to and during transcription elongation.

In this study, we demonstrate that efficient activation of PDR genes requires the chromatin reorganizing complex FACT, and that yeast defective in FACT function show increased sensitivity to xenobiotic drugs. PDR genes respond to toxin exposure with a rapid accumulation of PDR mRNA quickly followed by a subsequent reduction in transcript levels. This transcriptional induction and reduction is mirrored by sudden histone loss and repopulation across PDR loci, which allows direct analysis of FACT's effects on chromatin assembly and disassembly in a native context. PDR gene promoters contain Nucleosome Depleted Regions (NDRs), and thus FACT is not required for the same types of chromatin changes that occur at other promoters before gene activation, although FACT mutations cause minor delays in activation of PDR genes. Surprisingly, FACT mutants instead display a marked delay in repopulation of nucleosomes in the proximal promoter and open reading frame following cessation of transcription, revealing a novel role of FACT in chromatin reassembly in the wake of gene transcription.

Materials and Methods

For large-scale purification and identification of GST–Pdr1 AD-associated proteins, 6 L YPD medium (with 3% dextrose) was inoculated with yeast at an OD600 of 0.03 and grown at 30°C with shaking for approximately 13 hours, until an OD600 of ∼4. The cell pellet was then resuspended in 0.25 volumes of lysis buffer (50 mM Tris-HCl (pH 8.0), 400 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 0.1% NP40, 1 mM DTT, 0.25 mM PMSF, 1 mM benzamidine, 0.5 mg ml-1 aprotinin and Protease Inhibitor Cocktail (Complete, Roche)), and the suspension was quick-frozen in liquid nitrogen. Frozen cells were lysed by grinding with a mortar and pestle together with dry ice. One volume of lysis buffer was added after evaporation with dry ice, and the extract was spun at 4,000 g for 10 min. The supernatant was pre-incubated with 200 µl glutathione–Sepharose-bound GST for 2 h at 4°C with rotation, then it was incubated for another 3 h at 4°C with 200 µl glutathione–Sepharose-bound GST–Pdr1-AD (amino acids 966–1068), expressed and purified as described [22]. The beads were washed seven times with wash buffer (20 mM Tris-HCl, pH 8.0, 250 mM KCl, 0.1 mM EDTA, 10% glycerol, 0.1% NP-40, 5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.25 mM PMSF, 1 mM benzamidine and Protease Inhibitor Cocktail). The beads were finally washed once with low salt (150 mM NaCl) wash buffer. The bound proteins were then eluted with 500 μL of 0.3% sarkosyl in binding buffer for 1 h at 4°C and dialyzed overnight in 1 L of dialysis buffer (1% SDS, 1 mM β-mercaptoethanol and 1 mM Tris-HCl, pH 8.0). The dialyzed eluate was concentrated by dry-ice/ethanol SpeedVac to approximately 80 µl. The eluted proteins were resolved on 10% polyacrylamide gel and stained with Coomassie colloidal blue. Stained proteins were excised and subjected to trypsin digestion, followed by liquid chromatography MS/MS (LC-MS/MS) at the Taplin Biological Mass Spectrometry Facility at Harvard Medical School as previously described (Thakur et al. 2008).

Yeast strains and plasmids are listed in Table S1. For plate spot dilution growth assays, liquid cultures of the indicated strains at permissive temperature were grown to saturation, serially diluted in 10 fold increments, spotted onto YPAD agar media containing 0, 200, or 500 nM Ketoconazole (Sigma), incubated as denoted, and photographed.

Liquid culture growth rates were measured by diluting stock cultures grown for 24 hr at 25°C from single colonies in quadruplicate into fresh YPAD containing 0, 200, or 500 nM Ketoconazole, and incubating all cultures simultaneously in a Bioscreen-C Automated Growth Curve Analysis System (Growth Curves USA, Piscataway, NJ) for 24 hr at the indicated temperatures. Data consisting of OD600 measurements at 30 min intervals were analyzed and plotted using Prism 6.0c (GraphPad Software).

For gene expression and ChIP analysis, cells were cultured at the indicated temperature in 750 mL YPAD for 12–20 hr to a density of ∼1×107 cells/mL (OD660 = ∼0.75). For analysis of induction of PDR genes, aliquots were collected just prior to, and every 2.5 to 10 min after addition of Ketoconazole (Sigma) to 40 µM. ChIP samples were prepared by immediately adding formaldehyde at the designated time to a 50 mL culture aliquot to 1%, rocking at RT for 20 min, adding glycine to 125 mM, and immediately chilling on ice for 24 hr. Cells were then rinsed by centrifugation and resuspension twice in 1 volume of PBS, once in 1/50 volume of FA buffer [48], and the pelleted cells were flash frozen in liquid nitrogen, and stored at −80°C for processing.

For Myc, histone H3, and Spt16 immunoprecipitations, chromatin was prepared by cell lysis in 750 µL ice-cold ChIP Lysis Buffer (FA buffer containing 0.1% NP-40, 0.1% SDS, 5 mM MgCl2, 1 mM DTT, and protease inhibitors), and 1.2 mL pre-chilled 0.5 mm Zirconia/Silica beads in screw-cap microcentrifuge tubes using 6 cycles of 2 min each in a Mini-Bead-Beater 96 (Biospec Products), in a block chilled to −20°C, with 1 min chilling of the tubes on ice between each cycle. Recovered lysates were centrifuged 1 hr at 23 K rpm at 0°C, supernatant discarded, and the crude pellets were rinsed by partial resuspension in ice-cold 750 µL ChIP Lysis Buffer, and spun again for 15 min. For sonication, pellets were thoroughly resuspended with gentle probe sonication in fresh ChIP Lysis Buffer at 0°C, and chromatin was sheared by 60 cycles of a 30 sec burst followed by a 60 sec rest in a Bioruptor XL (Diagenode) at high power with circulating chilled water at 2°C. Debris was pelleted by centrifugation for 5 min at 23 K rpm at 0°C, and the soluble chromatin supernatant was aliquoted on ice, flash frozen in liquid nitrogen, and stored at −80°C. Chromatin shearing adequate for fine resolution analysis was confirmed by DNA gel electrophoresis of de-crosslinked and purified samples, and showed that the average fragment lengths were approximately 200 bp.

ChIP was carried out using 1 µg affinity purified anti-histone H3 C-terminus or anti-Myc (Mouse MAb 4A6, Upstate Biotechnology) or 5 µL anti–Spt16 serum rabbit polyclonal antibodies (Tim Formosa, University of Utah) pre-bound to approximately 3×107 anti-Rabbit IgG-coated magnetic beads (Invitrogen) per reaction. Immunoprecipitations contained chromatin with 500 µg protein content measured by BCA assay, beads, 1.5 mg/mL BSA, all in ChIP Lysis buffer as above, except with 0.01% SDS and 0.5 mM MgCl2 instead. Beads were washed for 5 min at 4°C twice with ChIP Lysis buffer as above, except with no SDS, twice with ChIP Lysis buffer as above, except with 500 mM NaCl and no SDS, and twice with ChIP Wash Buffer [48]. ChIP reactions were eluted from beads and de-crosslinked using Chelex-100 according to [49]. Aliquots of each input total chromatin corresponding to 25 µg protein content were de-crosslinked in parallel. Occupancy was measured by qPCR using primers for the indicated target and reference locations. SYBR-Green containing qPCR reactions with 1/4th to 1/20th dilution of the ChIP reaction and 1/200th to 1/1000th dilution of the input total chromatin were carried out in a Lightcycler LC480 (Roche), and were then quantified by also preparing a dilution set of the input total chromatin reactions analyzed in parallel to generate a standard curve, and calculating each target's relative concentration from the reaction's Cq using the manufacturer software. Levels of occupancy were compared between samples by first calculating a ChIP signal by dividing the relative concentration of a target in the ChIP reaction by that of the input chromatin to obtain a fraction or % IP value, then normalizing each ChIP signal to that for the IGR-I gene-free reference region on chromosome I [50]. Error bars for each point represent the propagated error from two to three PCR reactions each for the target sequence in the ChIP reaction and input, as well as for the reference sequence in the ChIP reaction and input, according to [51], [52]. Thus, a value of 1.0 on the y-axis in the figures corresponds to Histone H3 association, and thus inferred nucleosome occupancy equal to that of the non-expressed reference region, except where normalized to untreated samples.

RNA was prepared from corresponding 15 mL culture aliquots by adding Ethanol to 70%, then flash freezing the cell suspension in liquid nitrogen, and storing at −80°C for processing. RNA was isolated from frozen cell pellets by extraction with hot acid phenol, followed by precipitation through 5.7 M CsCl modified from [53]. Gene expression was analyzed by RT-qPCR, using randomly primed MMLV-RT (Promega) cDNA synthesis reactions containing 1 µg RNA. SYBR-Green containing qPCR reactions with 1/200th dilution of the RT reaction and using gene-specific primers (see Table S2) in a Lightcycler LC480 (Roche) were then quantified using pooled cDNA dilutions to generate standard curves as for the ChIP analysis [54]. Levels of PDR gene expression were compared between samples by normalizing each signal to the RPR1 internal reference transcript, or in certain indicated experiments to the RDN25 or the SCR1 internal reference.

Results

The Pdr1 transcription factor interacts with Gal11 and FACT

In order to identify proteins interacting with the Pdr1 transcriptional activator, we used the Pdr1 activation domain immobilized as a GST fusion protein for affinity chromatography, potentially bypassing any xenobiotic binding requirement on the activation domain. Specifically bound proteins eluting from the matrix were identified by mass spectrometry, and included both the Spt16 and Pob3 subunits of FACT, as well as the Gal11 subunit of Mediator (Fig. S1). We have previously shown that the KIX domain of Gal11 interacts with Pdr1, and that gal11 mutations diminish the PDR response [22]. Notably, mutations in some other Mediator components did not have this same effect [23]. Thus, identification in parallel of a known Pdr1-interacting factor necessary for PDR response serves as a positive control for the FACT-Pdr1 association, and suggests that recovery of FACT is physiologically significant.

FACT mutations affect antifungal sensitivity, and are additive with Mediator mutations

FACT has been shown to play a role in transcriptional activation at promoters [37], [46], [47] and to interact directly with the transcription factor SBF [55]. The Pdr1 – FACT interaction might also be direct, or it could involve intermediary bridging factors. Consistent with the latter possibility, we were unable to effectively co-immunoprecipitate Pdr1 with FACT. Previous work has shown that gal11 mutations confer sensitivity to xenobiotic drugs [22], so to test the relevance of FACT in PDR gene activation we asked whether FACT mutations have a similar effect by plating serial dilutions onto plates containing ketoconazole, an antifungal drug and inducer of PDR gene expression reviewed in [2], [56]. The FACT mutants show some growth defect in the presence of ketoconazole, and the FACT gal11 double mutants show a significant additive growth defect (Fig. 1). This suggests that Gal11 and FACT act in parallel on the same process in PDR.

thumbnail
Figure 1. Mutations in FACT sensitize cells to the antifungal ketoconazole.

A) Serial dilutions of DY150 (WT), DY5628 (gal11), DY6189 (spt16(G132D)), DY7230 (spt16-11), DY7379 (pob3(L78R)), or DY14202 (gal11 pob3(L78R)) were identically spotted onto YPAD agar plates lacking or containing 200 or 500 nM ketoconazole, grown under the indicated conditions, and then photographed. B) Dilute cultures of DY150 (WT) and DY8107 (spt16-11) were incubated in quadruplicate at the indicated temperatures in the absence or presence of 200 nM or 500 nM ketoconazole while OD600 was measured at 30 min. intervals and plotted as a function of incubation time. Error bars indicate the SEM of the four duplicate culture readings at each time point.

http://dx.doi.org/10.1371/journal.pone.0084092.g001

PDR expression and Mediator recruitment respond rapidly to antifungal exposure

PDR genes are expressed at modest levels in the absence of exogenous xenobiotic agents, but are rapidly induced to high levels following drug exposure (Fig. 2A and Fig. 3B) [17], [22]. In order to more precisely characterize the role of Gal11 in PDR gene activation, we treated logarithmically growing cells, wild type and gal11 mutants, with high dose (40 µM) ketoconazole, and harvested samples periodically over 40 min for RNA analysis and for Gal11 ChIP to measure Mediator recruitment. We observed a marked defect in the normally rapid PDR gene induction in gal11 mutant strains (Fig. 2A) and a similar defect in multiple FACT mutants with different growth conditions (Fig. S2 and Fig. S3). ChIP experiments show Gal11 is rapidly recruited to the PDR promoters following ketoconazole exposure (Fig. 2B), with the kinetics of Gal11 binding roughly correlating with gene activation. These experiments support the idea that both Gal11 and FACT are required for PDR gene activation, with the kinetics of Mediator recruitment suggesting a direct role in activation.

thumbnail
Figure 2. PDR genes are rapidly induced by drug treatment, in a Gal11 dependent process.

A) RT-qPCR analysis of several PDR gene RNAs from ketoconazole treated cultures of gal11 and FACT mutant strains: DY6129 (WT, black lines) vs. DY4257 (gal11, red lines) were grown to mid-log density at 25°C, temperature shifted to 37°C for 1 hr, 40 µM ketoconazole was added, and then samples were taken at the indicated times. RNA was isolated and RT-qPCR performed using primers targeting the transcribed regions of PDR5, PDR16, SNQ2, and YOR1, with results plotted as fold relative to the RDN25 reference transcript. B) ChIP with anti-Myc antibodies directed against C-terminally Myc tagged Gal11, from the same DY 6129 (WT) cultures as in A, using primers targeting the full UAS regions of several PDR genes encompassing the PDRE sequences for PDR5, PDR16, SNQ2, and YOR1. ChIP signals are expressed as fold enrichment relative to the intergenic IGR-I reference target, and are normalized to non drug-treated samples. Error Bars represent the SD of three replicate qPCR reactions. Data presented are representative of two to three independently replicated experiments. See Table S2 for primer sequences.

http://dx.doi.org/10.1371/journal.pone.0084092.g002

thumbnail
Figure 3. Nucleosome depletion and re-deposition across PDR5 during induction by exposure to ketoconazole.

A) Histone H3 ChIP was used to measure nucleosome occupancy at the indicated regions relative to the gene-free IGR-I region across the PDR5 promoter and ORF in a DY150 (WT) strain grown @ 30°, using these primers: PDR5 Upstream (F2710- F2711), PDR5 UAS-L (primers F2460- F2712), PDR5 UAS-R (primers F3229- F3230), PDR5 TATA (primers F2488-F2489), and PDR5 ORF (primers F3198-F3199). Error Bars represent the SD for three biological replicate cultures. Results show the relatively depleted region encompassing the Pdr1 and Yap1 binding sites in the promoter as shown in C, with higher occupancy elsewhere. B) RT-qPCR analysis of several PDR gene RNAs (using PDR5, PDR15, PDR16, SNQ2, and YOR1 ORF primer sets) from DY150 (WT) cells treated with a 60 min. timecourse of ketoconazole, plotted as fold relative to the RPR1 reference transcript. Gene expression was normalized to the basal levels prior to treatment. Error Bars represent the data range of duplicate RT and qPCR reactions. C) Diagram of the PDR5 promoter and ORF, showing relative positions of nucleosomes (ovals) based on data from [57][59], PDRE (potential Pdr1 binding sites) and Yap1 sites, the TATA, TSS, and ATG, and PCR target amplicons. D) Histone H3 ChIP was used to measure nucleosome loss and re-deposition at the indicated regions relative to IGR-I across PDR5 just before and at intervals for 1 hour after addition of ketoconazole to DY150 (WT) cultures. Values are calculated as in A. Error Bars represent the SD of three replicate qPCR reactions. Data presented in 3B and 3C are typical of experiments independently repeated at least six times. See Table S2 for primer sequences.

http://dx.doi.org/10.1371/journal.pone.0084092.g003

Transcriptional response and histone occupancy of PDR genes is rapid and dynamic

In order to understand the role of FACT and chromatin in the PDR response, we first analyzed nucleosome occupancy by using Histone H3 ChIP assays in the promoter and coding regions in the absence of toxin treatment. For our chromatin studies we focused on the canonical Pdr1 target PDR5, encoding a prominent drug efflux pump, and determined H3 binding in the uninduced state. We used five sets of PCR primers, for the far upstream region, two parts of the Upstream Activating Region (UAS-L and UAS-R), the TATA region, and within the transcribed ORF (see diagram in Fig. 3C). The ChIP experiments in Fig. 3A clearly show that the PDR5 UAS is within a Nucleosome Depleted Region (NDR), consistent with whole-genome analyses of histone occupancy [57][59]. (As described in Methods, for all histone H3 ChIP assays a value of 1 on the y-axis corresponds to the inferred nucleosome occupancy seen at a gene-free reference region on chromosome I.).

We first analyzed the kinetics of the transcriptional response and changes in chromatin structure in wild type cells grown at the standard temperature of 30°C. Cells were treated with ketoconazole and samples were taken periodically over 60 minutes for both RNA analysis and for histone H3 ChIP to measure nucleosome occupancy. RT-qPCR was used to measure mRNA levels for five genes of the PDR regulon, including PDR5, and the results show rapid induction, visible at the first time point (5 min), a peak at 15 to 25 min, and a return to baseline at 40 to 50 min (Fig. 3B). Normalizing the data for each gene to transcript levels in untreated cells, induction levels of 4 to 16 fold are seen.

The time course ChIP experiments (Fig. 3D) show an immediate depletion of histones at 5 min following drug addition in the TATA and ORF regions, and even within the UAS which contains sufficiently low histone occupancy to be described as an NDR. Surprisingly, this histone loss is also seen upstream of the UAS, suggesting that effects on chromatin from drug binding by the Pdr1 factor can be propagated bi-directionally. After the initial rapid loss, histone H3 signal begins to return to the upstream regions first, with detectable repopulation by 10 minutes, while the signal remains transiently depleted across the entire promoter and transcription unit. Nucleosome loss across the promoter and coding region persists until about 25 minutes, and returns to the full basal occupancy conditions at 40 to 50 minutes, even though drug is still present. Note that nucleosome binding is inversely correlated with PDR5 transcription.

Altered chromatin dynamics at PDR5 in FACT mutant strains

We next asked how FACT defects affect the dynamics of chromatin alterations at PDR genes during activation and repression. Most FACT mutations are temperature sensitive for growth [31], and many studies, including those in Fig. S2, utilize a temperature shift protocol in order to reveal FACT defects. However, such procedures also induce a heat shock response, and this will lead to activation of many PDR genes because most of these genes, including PDR1 and PDR3, also contain binding sites for the heat shock-induced Hsf1 and/or Yap1 factors adjacent to the Pdr1 binding sites [60], [61] (also see Fig. 3C). For this reason we wanted to avoid a sudden change in temperature in our studies. To this end, growth curves were generated for wild type and spt16-11 (aa T828I, P859S) mutant strains grown continuously in liquid culture at various temperatures in the presence and absence of ketoconazole (Fig. 1B). At the semi-permissive temperature of 36°C the spt16-11 mutant grows very poorly, while at 34°C the spt16-11 strain displays relatively normal growth characteristics in the absence of added drug. We decided to use the spt16-11 mutant grown at 34°C in subsequent experiments; importantly, under these conditions ketoconazole inhibits growth in a dose-dependent manner (Fig. 1B, middle panel). In our experiments, the wild type and spt16-11 strains were cultivated at 34°C continuously for at least 12 hours to attain mid-log density before addition of drug, allowing temperature adaptation and thus avoiding any heat shock effects.

We first studied wild type and spt16-11 mutant cells grown at 34°C in the absence of drug, measuring PDR5 mRNA levels by RT-qPCR and examining PDR5 chromatin architecture by histone H3 ChIP. Basal expression of PDR5 is reduced about 3-fold in the spt16-11 mutant (Fig. 4B). Similar mild reductions are seen at several other PDR genes in spt16-11 (e.g., PDR16 and SNQ2) and with several other mutant FACT alleles (Fig. S2 and Fig. S3), indicating this effect is not FACT allele-specific, nor due to the normalization methods. Chromatin structure at PDR genes in wild type cells at 34°C is similar (Fig. 4C) to that seen at 30°C (Fig. 3A), as evidenced by histone H3 ChIP signals. In spt16-11 cells at 34°C, the NDR is still present at the PDR5 promoter, but the histone H3 ChIP signals in more highly occupied locations are somewhat reduced (Fig. 4C), suggesting FACT-dependent alterations to chromatin architecture in the absence of toxin. To determine whether the nucleosome occupancy levels at PDR5 are directly due to FACT, Spt16 ChIPs were performed in uninduced wild type or spt16-11 cells (Fig. 4D). FACT occupancy mirrors that of nucleosomes at this gene, with Spt16 ChIP signals relatively increased at those locations with higher histone H3 ChIP signals, but with signals at or below background levels in the NDR region of the PDR5 UAS. To address the specificity of the Spt16 ChIP signals, the spt16-11 negative control ChIP (Fig. 4D, open bars) was performed because the specific enrichment of wild type FACT at any particular gene relative to control is usually mild, probably due to FACT binding activity throughout the genome. Inactive mutant FACT protein levels are probably quite reduced at this semi-permissive temperature in mutant cells, based on the reduced levels seen in Western blots at the non-permissive temperature of 37°C [62], and loss of FACT function under these conditions has been observed in other assays [63]. The low enrichment values for FACT binding across PDR5 in the spt16-11 strain grown at 34°C thus define ChIP background signals. However, the small reductions from loss of FACT binding and function in both expression (∼3-fold) and histone occupancy in non-drug treated cells are unlikely to account for the observed defects in the PDR phenotype.

thumbnail
Figure 4. spt16-11 alters histone binding across PDR5.

A) Diagram of PDR5 as in Fig. 3. B) RT-qPCR analysis of PDR5 RNA from non-drug treated DY150 (WT, filled bars) or DY8107 (spt16-11, open bars) cells, both grown at 34° and normalized to RPR1 reference transcripts, and plotted relative to WT levels. C) ChIP analysis using antibodies against histone H3 at the indicated locations in PDR5 from the same non-drug treated WT or spt16-11 strains as above, normalized to an intergenic region on chromosome I (IGR-I) as a reference control. D) ChIP analysis using antibodies against Spt16 similarly to C. For all graphs, error bars represent the SD for three biological replicate cultures.

http://dx.doi.org/10.1371/journal.pone.0084092.g004

To address the hypothesis that the effects of FACT loss are more important to dynamic changes in PDR induction upon drug exposure rather than basal expression, we next added 40 µM ketoconazole to wild type and spt16-11 cells grown continuously at 34°C. PDR5 mRNA was measured by RT-qPCR (Fig. 5B) and histone H3 occupancy across PDR5 was assayed by ChIP (Fig. 5C), over a longer period and with more frequent sampling for finer resolution. PDR5 induction occurs somewhat faster in wild type cells at this temperature. Importantly, the amplitude of PDR5 RNA accumulation and the rate of increase were both lowered in the spt16-11 strain (Fig. 5B), and similar reductions and delays were also seen at other PDR genes (Fig. S3, which also includes the same data from Fig. 5B for comparison), with the time of peak mRNA abundance delayed by at least 10 min relative to WT. The transcription of PMA1, encoding the membrane H+ ATPase required for PDR, but not regulated by Pdr1, [64], [65] did not show a similar profile of FACT-dependent induction, indicating that this burst of transcription is not a general response (Fig. S3). Time course gene expression experiments with the other mutant FACT alleles also show defects in PDR gene induction in response to xenobiotic drugs (Fig. S2). In contrast, a gal11 mutation affecting Mediator function causes a much more severe defect in PDR gene induction (Fig. 2A) [22].

thumbnail
Figure 5. Kinetics of induction and nucleosome re-deposition at PDR5 correspond to FACT occupancy, and are defective in a FACT mutant.

DY5699 (WT, black lines) and DY8107 (spt16-11, red lines) cultures were grown at 34°C and treated with ketoconazole, with samples collected every 2.5, 5, or 10 min. for ChIP and RNA during 60 minutes of exposure. RNA (5B) and ChIP (5C and 5D) analyses were as in Fig. 3 and Fig. 4, at locations in PDR5 shown in 5A. C) H3 ChIP across PDR5 during drug induction, showing rapid nucleosome loss and differences in repopulation. D) Chromatin samples from the same collection as those in Fig. 5C were analyzed by ChIP using antibodies against Spt16 for FACT recruitment to PDR5. Data are reported as Fold ChIP signal relative to the gene-free IGR-I region. Error bars represent the data range for two biological replicate cultures.

http://dx.doi.org/10.1371/journal.pone.0084092.g005

Histone H3 chromatin binding measurements upon ketoconazole induction throughout the PDR5 promoter and ORF were then undertaken. These time course experiments showed a rapid loss of histone H3 ChIP signal upon ketoconazole addition in the upstream, TATA and ORF regions, with minimum occupancy at 2.5 to 5 min after drug treatment in wild type cells (Fig. 5C). Importantly, this rapid loss was observed in both wild type and spt16-11 cells, notwithstanding the transcriptional induction defects observed in spt16-11 at the same time, although there may be a slightly delayed eviction in the absence of FACT. This analysis concluded that nucleosome occupancy was rapidly restored to pre-induction levels in wild type cells. However, although FACT mutants exhibited nucleosome loss with kinetics similar to wild type cells, the spt16-11 mutant exhibited a marked defect in the ability to repopulate chromatin to the pre-induction level of histone occupancy compared to wild type. Histone H3 association was still deficient 60 min following drug addition in the FACT mutant, while in wild type, nucleosomes were fully repopulated by 30 min. This same overall pattern of nucleosome binding dynamics is reproducibly seen for several genes in the PDR regulon (Fig. S4).

ChIPs were performed with anti-Spt16 antibody to measure FACT recruitment to PDR5 during the time course described for Fig. 5B and 5C. As shown in Fig. 5D, there is a low amount of FACT binding to the ORF before induction, but FACT occupancy increases during the initial chromatin disassembly phase that accompanies gene induction (10 min). Substantially more FACT binding is seen after gene expression has ended, coinciding with the time of nucleosome repopulation (30 min). Relatively little FACT is recruited to the NDR region at the UAS.

Discussion

Transcriptional activation of the PDR genes is unusual because the Pdr1 transcription factor is always promoter-bound, even in the absence of inducers. Upon binding to xenobiotic agents the large carboxyl-terminal domain harboring the activation domain of Pdr1 changes in unknown ways to facilitate gene activation. This transcriptional response requires the Gal11 subunit of Mediator, and here we show that there is rapid recruitment of Gal11 to PDR gene promoters coincident with the sudden burst of gene activation.

Mass spectroscopy of Pdr1 interacting proteins detected the Spt16 and Pob3 subunits of the FACT chromatin reorganizing complex, and we find that FACT affects PDR gene expression in unexpected ways. FACT mutants show an increased sensitivity to xenobiotic drugs and a decrease in both basal and induced PDR gene expression. At some promoters, sequence-specific DNA-binding factors recruit FACT, which can then facilitate nucleosome eviction at promoters as a prelude to gene activation [46], [47], [66]. We expected a similar scenario at the PDR genes. However, the promoters of these genes have regions spanning the PDREs that are already largely nucleosome free without stimulation, in addition to constitutive occupancy by Pdr1, and thus the promoters do not require nucleosome eviction before their rapid transcriptional response. We could not detect additional FACT recruited to PDR gene control elements during induction, possibly due to the reduced presence of its nucleosomal substrate there, but only to transcribed regions, consistent with FACT's proposed roles in elongation. Further work is needed to determine if the FACT binding signals observed in the proximal promoter TATA region of PDR5 could be distinct from that in the elongation region, or is a limitation of the resolution of the ChIP assay. It is notable that FACT is recruited to the ORF in two phases: The first coincides with nucleosome loss as transcription is induced, and the second phase occurs concurrent with nucleosome reassembly following conclusion of transcription. This biphasic profile of recruitment is similar to that seen at CLN genes during cell-cycle induction in G1 [55]. The major defect observed in FACT mutants at PDR genes was a marked delay in repopulation of nucleosomes after transcription ceases in this second phase.

This defect in nucleosome repopulation is consistent with FACT's proposed roles in both nucleosome disassembly and reassembly [29]. FACT mutant phenotypes of cryptic promoter activation [40], [43], failure to rebuild properly repressive chromatin [67], and enhanced rates of histone replacement [68] support models in which FACT is required for nucleosome reassembly. Experiments presented in this work were carried out such that the rapid kinetics of the PDR gene response were able to be measured, and moreover the effects of FACT on the dynamic processes of nucleosome disassembly and reassembly during a natural cycle of induction and resolution could be directly observed in chromatin composed of WT histones at native levels of abundance, in contrast to previous approaches. Most surprisingly, FACT mutations reduce both basal expression of PDR genes as well as the rate of gene induction, even though chromatin looks normal in the gene promoter. Why does a failure to reassemble nucleosomes over PDR genes lead to reduced gene expression and a drug resistance defect, rather than to a derepressed transcriptional status? While there is a somewhat delayed return to uninduced levels at some PDR genes in FACT mutant cells, it seems likely that the observed transcriptional defects in FACT mutants are probably due to aberrant reassembly of chromatin following DNA replication in drug-free cells, as the PDR genes have not been induced for many generations in our experimental setup. Further analysis of the role of FACT in determining the nature of PDR gene chromatin will be required.

PDR in fungi, and MDR more generally, occur in pathogenic conditions and must be managed for successful clinical outcomes. Understanding the roles of coactivators and modifiers of chromatin at ABC transporter genes define prominent molecular targets, which may allow the design of adjunct drug therapies targeting these proteins that would inhibit resistance to antifungals or chemotherapeutics. Moreover, drugs which interfere with factors that modify chromatin, with FACT among them, have been explored as chemotherapeutic agents [69], [70], however these may have unintended consequences for altering ABC gene expression, both by activating MDR, as well as interfering with chromatin regulators at those genes, and therefore enhancing resistance in unexpected ways. A thorough understanding of all factors involved in MDR gene regulation will allow rational intervention design to clinically manage this phenomenon.

Supporting Information

Figure S1.

Yeast FACT and Gal11 bind to the Pdr1 activation domain.

doi:10.1371/journal.pone.0084092.s001

(PDF)

Figure S2.

Altered PDR5 expression kinetics observed in other FACT mutants.

doi:10.1371/journal.pone.0084092.s002

(PDF)

Figure S3.

SPT16 mutation reduces and/or delays the kinetics of antifungal induced expression of multiple PDR genes.

doi:10.1371/journal.pone.0084092.s003

(PDF)

Figure S4.

Many genes in the PDR regulon show histone binding alterations during ketoconazole induction.

doi:10.1371/journal.pone.0084092.s004

(PDF)

Table S1.

Yeast Strains and Plasmids.

doi:10.1371/journal.pone.0084092.s005

(PDF)

Table S2.

Oligonucleotide List.

doi:10.1371/journal.pone.0084092.s006

(PDF)

Acknowledgments

We thank Tim Formosa for many helpful discussions throughout this project.

Author Contributions

Conceived and designed the experiments: WPV ST AMN DJS. Performed the experiments: WPV ST JN BMM. Analyzed the data: WPV ST JN AMN DJS. Wrote the paper: WPV ST AMN DJS.

References

  1. 1. Monk BC, Goffeau A (2008) Outwitting multidrug resistance to antifungals. Science (New York, NY) 321: 367–369.
  2. 2. Miceli MH, Diaz JA, Lee SA (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11: 142–151.
  3. 3. Cheng SC, Joosten LA, Kullberg BJ, Netea MG (2012) Interplay between Candida albicans and the mammalian innate host defense. Infect Immun 80: 1304–1313.
  4. 4. Selmecki A, Forche A, Berman J (2006) Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313: 367–370.
  5. 5. Albers SV, Koning SM, Konings WN, Driessen AJ (2004) Insights into ABC transport in archaea. J Bioenerg Biomembr 36: 5–15.
  6. 6. Colabufo NA, Berardi F, Contino M, Niso M, Perrone R (2009) ABC pumps and their role in active drug transport. Curr Top Med Chem 9: 119–129.
  7. 7. Lee SJ, Bohm A, Krug M, Boos W (2007) The ABC of binding-protein-dependent transport in Archaea. Trends Microbiol 15: 389–397.
  8. 8. Seeger MA, van Veen HW (2009) Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta 1794: 725–737.
  9. 9. Stavrovskaya AA, Stromskaya TP (2008) Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 73: 592–604.
  10. 10. Bauer BE, Wolfger H, Kuchler K (1999) Inventory and function of yeast ABC proteins: about sex, stress, pleiotropic drug and heavy metal resistance. Biochimica et biophysica acta 1461: 217–236.
  11. 11. Decottignies A, Goffeau A (1997) Complete inventory of the yeast ABC proteins. Nature genetics 15: 137–145.
  12. 12. Klein C, Kuchler K, Valachovic M (2011) ABC proteins in yeast and fungal pathogens. Essays in Biochemistry 50: 101–119.
  13. 13. Rogers B, Decottignies A, Kolaczkowski M, Carvajal E, Balzi E, et al. (2001) The pleitropic drug ABC transporters from Saccharomyces cerevisiae. Journal of molecular microbiology and biotechnology 3: 207–214.
  14. 14. Golin J, Ambudkar S, May L (2007) The yeast Pdr5p multidrug transporter: How does it recognize so many substrates? Biochemical and Biophysical Research Communications 356: 1–5.
  15. 15. Naar AM, Thakur JK (2009) Nuclear receptor-like transcription factors in fungi. Genes Dev 23: 419–432.
  16. 16. Balzi E, Goffeau A (1995) Yeast multidrug resistance: the PDR network. Journal of bioenergetics and biomembranes 27: 71–76.
  17. 17. Fardeau V, Lelandais G, Oldfield A, Salin H, Lemoine S, et al. (2007) The central role of PDR1 in the foundation of yeast drug resistance. The Journal of biological chemistry 282: 5063–5074.
  18. 18. Katzmann D, Burnett P, Golin J, Mahe Y, Moye-Rowley W (1994) Transcriptional control of the yeast PDR5 gene by the PDR3 gene product. Molecular and Cellular Biology 14: 4653.
  19. 19. Schjerling P, Holmberg S (1996) Comparative amino acid sequence analysis of the C6 zinc cluster family of transcriptional regulators. Nucleic Acids Res 24: 4599–4607.
  20. 20. Gao C, Wang L, Milgrom E, Shen W-CW (2004) On the mechanism of constitutive Pdr1 activator-mediated PDR5 transcription in Saccharomyces cerevisiae: evidence for enhanced recruitment of coactivators and altered nucleosome structures. The Journal of biological chemistry 279: 42677–42686.
  21. 21. Borecka-Melkusova S, Kozovska Z, Hikkel I, Dzugasova V, Subik J (2008) RPD3 and ROM2 are required for multidrug resistance in Saccharomyces cerevisiae. FEMS Yeast Res 8: 414–424.
  22. 22. Thakur JK, Arthanari H, Yang F, Pan S-J, Fan X, et al. (2008) A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 452: 604–609.
  23. 23. Shahi P, Gulshan K, Näär AM, Moye-Rowley WS (2010) Differential roles of transcriptional mediator subunits in regulation of multidrug resistance gene expression in Saccharomyces cerevisiae. Molecular biology of the cell 21: 2469–2482.
  24. 24. Orphanides G, LeRoy G, Chang CH, Luse DS, Reinberg D (1998) FACT, a factor that facilitates transcript elongation through nucleosomes. Cell 92: 105–116.
  25. 25. Malone EA, Clark CD, Chiang A, Winston F (1991) Mutations in SPT16/CDC68 suppress cis- and trans-acting mutations that affect promoter function in Saccharomyces cerevisiae. Mol Cell Biol 11: 5710–5717.
  26. 26. Bruhn SL, Pil PM, Essigmann JM, Housman DE, Lippard SJ (1992) Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci U S A 89: 2307–2311.
  27. 27. Yarnell AT, Oh S, Reinberg D, Lippard SJ (2001) Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin. J Biol Chem 276: 25736–25741.
  28. 28. Stillman DJ (2010) Nhp6: a small but powerful effector of chromatin structure in Saccharomyces cerevisiae. Biochim Biophys Acta 1799: 175–180.
  29. 29. Formosa T (2012) The role of FACT in making and breaking nucleosomes. Biochimica et biophysica acta 1819: 247–255.
  30. 30. Formosa T (2008) FACT and the reorganized nucleosome. Molecular bioSystems 4: 1085–1093.
  31. 31. Formosa T, Eriksson P, Wittmeyer J, Ginn J, Yu Y, et al. (2001) Spt16-Pob3 and the HMG protein Nhp6 combine to form the nucleosome-binding factor SPN. Embo J 20: 3506–3517.
  32. 32. Kemble DJ, Whitby FG, Robinson H, McCullough LL, Formosa T, et al. (2013) Structure of the Spt16 middle domain reveals functional features of the histone chaperone FACT. J Biol Chem 288: 10188–10194.
  33. 33. Hondele M, Stuwe T, Hassler M, Halbach F, Bowman A, et al. (2013) Structural basis of histone H2A-H2B recognition by the essential chaperone FACT. Nature 499: 111–114.
  34. 34. Xin H, Takahata S, Blanksma M, McCullough L, Stillman DJ, et al. (2009) yFACT induces global accessibility of nucleosomal DNA without H2A-H2B displacement. Mol Cell 35: 365–376.
  35. 35. Wittmeyer J, Formosa T (1997) The Saccharomyces cerevisiae DNA polymerase alpha catalytic subunit interacts with Cdc68/Spt16 and with Pob3, a protein similar to an HMG1-like protein. Molecular and Cellular Biology 17: 4178–4190.
  36. 36. Schlesinger MB, Formosa T (2000) POB3 is required for both transcription and replication in the yeast Saccharomyces cerevisiae. Genetics 155: 1593–1606.
  37. 37. Biswas D, Yu Y, Prall M, Formosa T, Stillman DJ (2005) The yeast FACT complex has a role in transcriptional initiation. Mol Cell Biol 25: 5812–5822.
  38. 38. Krogan NJ, Kim M, Ahn SH, Zhong G, Kobor MS, et al. (2002) RNA polymerase II elongation factors of Saccharomyces cerevisiae: a targeted proteomics approach. Mol Cell Biol 22: 6979–6992.
  39. 39. Simic R, Lindstrom DL, Tran HG, Roinick KL, Costa PJ, et al. (2003) Chromatin remodeling protein Chd1 interacts with transcription elongation factors and localizes to transcribed genes. Embo J 22: 1846–1856.
  40. 40. Mason PB, Struhl K (2003) The FACT complex travels with elongating RNA polymerase II and is important for the fidelity of transcriptional initiation in vivo. Molecular and Cellular Biology 23: 8323–8333.
  41. 41. Saunders A, Werner J, Andrulis ED, Nakayama T, Hirose S, et al. (2003) Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo. Science 301: 1094–1096.
  42. 42. Belotserkovskaya R, Oh S, Bondarenko VA, Orphanides G, Studitsky VM, et al. (2003) FACT facilitates transcription-dependent nucleosome alteration. Science 301: 1090–1093.
  43. 43. Kaplan C, Laprade L, Winston F (2003) Transcription elongation factors repress transcription initiation from cryptic sites. Science 301: 1096.
  44. 44. Biswas D, Dutta-Biswas R, Mitra D, Shibata Y, Strahl BD, et al. (2006) Opposing roles for Set2 and yFACT in regulating TBP binding at promoters. Embo J 25: 4479–4489.
  45. 45. Biswas D, Dutta-Biswas R, Stillman DJ (2007) Chd1 and yFACT act in opposition in regulating transcription. Mol Cell Biol 27: 6279–6287.
  46. 46. Takahata S, Yu Y, Stillman DJ (2009) FACT and Asf1 regulate nucleosome dynamics and coactivator binding at the HO promoter. Mol Cell 34: 405–415.
  47. 47. Ransom M, Williams SK, Dechassa ML, Das C, Linger J, et al. (2009) FACT and the proteasome promote promoter chromatin disassembly and transcriptional initiation. J Biol Chem 284: 23461–23471.
  48. 48. Strahl-Bolsinger S, Hecht A, Luo K, Grunstein M (1997) SIR2 and SIR4 interactions differ in core and extended telomeric heterochromatin in yeast. Genes Dev 11: 83–93.
  49. 49. Nelson JD, Denisenko O, Sova P, Bomsztyk K (2006) Fast chromatin immunoprecipitation assay. Nucleic Acids Res 34: e2.
  50. 50. Mason PB, Struhl K (2005) Distinction and relationship between elongation rate and processivity of RNA polymerase II in vivo. Mol Cell 17: 831–840.
  51. 51. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N (2007) Statistical significance of quantitative PCR. BMC Bioinformatics 8: 131.
  52. 52. van Kempen GM, van Vliet LJ (2000) Mean and variance of ratio estimators used in fluorescence ratio imaging. Cytometry 39: 300–305.
  53. 53. Ausubel FM, Brent R, Kingston RE, Moore DE, Seidman JG, et al.. (1987) Current Protocols in Molecular Biology. New York: Wiley and Sons.
  54. 54. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611–622.
  55. 55. Takahata S, Yu Y, Stillman DJ (2009) The E2F functional analogue SBF recruits the Rpd3(L) HDAC, via Whi5 and Stb1, and the FACT chromatin reorganizer, to yeast G1 cyclin promoters. Embo J 28: 3378–3389.
  56. 56. Kolaczkowska A, Goffeau A (1999) Regulation of pleiotropic drug resistance in yeast. Drug Resistance Updates 2: 403–414.
  57. 57. Yuan GC, Liu YJ, Dion MF, Slack MD, Wu LF, et al. (2005) Genome-scale identification of nucleosome positions in S. cerevisiae. Science 309: 626–630.
  58. 58. Lee W, Tillo D, Bray N, Morse RH, Davis RW, et al. (2007) A high-resolution atlas of nucleosome occupancy in yeast. Nat Genet 39: 1235–1244.
  59. 59. Whitehouse I, Rando OJ, Delrow J, Tsukiyama T (2007) Chromatin remodelling at promoters suppresses antisense transcription. Nature 450: 1031–1035.
  60. 60. Ma M, Liu ZL (2010) Comparative transcriptome profiling analyses during the lag phase uncover YAP1, PDR1, PDR3, RPN4, and HSF1 as key regulatory genes in genomic adaptation to the lignocellulose derived inhibitor HMF for Saccharomyces cerevisiae. BMC Genomics 11: 660.
  61. 61. Wendler F, Bergler H, Prutej K, Jungwirth H, Zisser G, et al. (1997) Diazaborine resistance in the yeast Saccharomyces cerevisiae reveals a link between YAP1 and the pleiotropic drug resistance genes PDR1 and PDR3. J Biol Chem 272: 27091–27098.
  62. 62. VanDemark AP, Xin H, McCullough L, Rawlins R, Bentley S, et al. (2008) Structural and functional analysis of the Spt16p N-terminal domain reveals overlapping roles of yFACT subunits. J Biol Chem 283: 5058–5068.
  63. 63. McCullough L, Rawlins R, Olsen A, Xin H, Stillman DJ, et al. (2011) Insight into the mechanism of nucleosome reorganization from histone mutants that suppress defects in the FACT histone chaperone. Genetics 188: 835–846.
  64. 64. Capieaux E, Vignais ML, Sentenac A, Goffeau A (1989) The yeast H+-ATPase gene is controlled by the promoter binding factor TUF. J Biol Chem 264: 7437–7446.
  65. 65. Garcia-Arranz M, Maldonado AM, Mazon MJ, Portillo F (1994) Transcriptional control of yeast plasma membrane H(+)-ATPase by glucose. Cloning and characterization of a new gene involved in this regulation. J Biol Chem 269: 18076–18082.
  66. 66. Lolis AA, Londhe P, Beggs BC, Byrum SD, Tackett AJ, et al. (2013) Myogenin recruits the histone chaperone facilitates chromatin transcription (FACT) to promote nucleosome disassembly at muscle-specific genes. J Biol Chem 288: 7676–7687.
  67. 67. Hainer SJ, Pruneski JA, Mitchell RD, Monteverde RM, Martens JA (2011) Intergenic transcription causes repression by directing nucleosome assembly. Genes & Development 25: 29–40.
  68. 68. Jamai A, Puglisi A, Strubin M (2009) Histone Chaperone Spt16 Promotes Redeposition of the Original H3-H4 Histones Evicted by Elongating RNA Polymerase. Molecular Cell 35: 377–383.
  69. 69. Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, et al. (2011) Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Sci Transl Med 3: 95ra74.
  70. 70. Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, et al. (2012) Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer Prev Res (Phila) 5: 1025–1035.